Dexamethasone in hospitalized patients with COVID-19 preliminary report: Discussions from the respirology and sleep Twitter journal club @respandsleepjc (#rsjc)

Ahmed, Waleed; Anand, Anju; Stanbrook, Matthew B.

doi:10.1080/24745332.2021.1920865

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The existing antivirals and antimalarials in the allopathy system such as remdesivir, favipiravir, ribavirin, lopinavir, ritonavir, darunavir, arbidol, chloroquine, hydroxychloroquine, and interferons have been repurposed in the recent past due to its proven inhibitory effects against the SARS-CoV-2 ( 6 ). In prior studies, the drug Dexamethasone was found to offer 28-day lower mortality in hospitalized, critically ill COVID-19 patients ( 7 ). Hence, there is a dire need for interventions that can prevent COVID-19 disease progression and fatalities.…”

Section: Introductionmentioning

confidence: 99%